Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sally Moore

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Journal of Health Services Research & Policy|December 14, 2017
Patient-reported safety incidents as a new source of patient safety data: an exploratory comparative study in an acute hospital in EnglandGerry Armitage, Sally Moore, Caroline Reynolds, et al.
British Journal of Haematology|December 4, 2019
Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experienceFaouzi Djebbari, Huben Hubenov, Pratap Neelakantan, et al.
Journal of Clinical Monitoring and Computing|December 19, 2023
Impact of clinicians' behavior, an educational intervention with mandated blood pressure and the hypotension prediction index software on intraoperative hypotension: a mixed methods studyIlonka N de Keijzer, Jaap Jan Vos, David Yates, et al.
Exercise Immunology Review|April 22, 2022
The effects of exercise on complement system proteins in humans: a systematic scoping reviewDaniela Rothschild-Rodriguez, Adam J Causer, Frankie F Brown, et al.
European Journal of Haematology|January 9, 2013
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myelomaSally Moore, Sangeeta Atwal, Sajitha Sachchithanantham, et al.
Frontiers in Oncology|September 8, 2023
Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative reviewHarrison D Collier-Bain, Frankie F Brown, Adam J Causer, et al.
BMJ Quality & Safety|February 5, 2017
Can patient involvement improve patient safety? A cluster randomised control trial of the Patient Reporting and Action for a Safe Environment (PRASE) interventionRebecca Lawton, Jane Kathryn O'Hara, Laura Sheard, et al.
Haematologica|October 15, 2020
Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of careFaouzi Djebbari, Fotios Panitsas, Toby A Eyre, et al.
British Journal of Haematology|December 16, 2020
Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK)Faye A Sharpley, Jemma Larham, Angus Haines, et al.
European Journal of Haematology|February 20, 2022
Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunityJennifer L J Heaney, Sian Faustini, Lili Evans, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Journal of Health Services Research & Policy|December 14, 2017
Patient-reported safety incidents as a new source of patient safety data: an exploratory comparative study in an acute hospital in EnglandGerry Armitage, Sally Moore, Caroline Reynolds, et al.
British Journal of Haematology|December 4, 2019
Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experienceFaouzi Djebbari, Huben Hubenov, Pratap Neelakantan, et al.
Journal of Clinical Monitoring and Computing|December 19, 2023
Impact of clinicians' behavior, an educational intervention with mandated blood pressure and the hypotension prediction index software on intraoperative hypotension: a mixed methods studyIlonka N de Keijzer, Jaap Jan Vos, David Yates, et al.
Exercise Immunology Review|April 22, 2022
The effects of exercise on complement system proteins in humans: a systematic scoping reviewDaniela Rothschild-Rodriguez, Adam J Causer, Frankie F Brown, et al.
European Journal of Haematology|January 9, 2013
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myelomaSally Moore, Sangeeta Atwal, Sajitha Sachchithanantham, et al.
Frontiers in Oncology|September 8, 2023
Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative reviewHarrison D Collier-Bain, Frankie F Brown, Adam J Causer, et al.
BMJ Quality & Safety|February 5, 2017
Can patient involvement improve patient safety? A cluster randomised control trial of the Patient Reporting and Action for a Safe Environment (PRASE) interventionRebecca Lawton, Jane Kathryn O'Hara, Laura Sheard, et al.
Haematologica|October 15, 2020
Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of careFaouzi Djebbari, Fotios Panitsas, Toby A Eyre, et al.
British Journal of Haematology|December 16, 2020
Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK)Faye A Sharpley, Jemma Larham, Angus Haines, et al.
European Journal of Haematology|February 20, 2022
Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunityJennifer L J Heaney, Sian Faustini, Lili Evans, et al.
Pageof 7